Literature DB >> 11748927

Differentiation of resting human peripheral blood gamma delta T cells toward Th1- or Th2-phenotype.

D Wesch1, A Glatzel, D Kabelitz.   

Abstract

Depending on the microenvironment, murine gamma delta T cells differentiate into either Th1 (IFN-gamma-producing) or Th2 (IL-4-producing) cells. It is unclear, however, whether circulating human peripheral blood gamma delta T cells can be driven into Th1 or Th2 cells by modulation of the priming cytokine milieu. In this study, peripheral blood gamma delta T cells were stimulated by phosphoantigen (isopentenyl pyrophosphate) or Daudi lymphoma cells in the presence of Th1-priming (rIL-12, anti-IL-4 Ab) or Th2-priming (rIL-4, anti-IL-12 Ab) conditions. Single-cell analysis of cytokine secretion (IFN-gamma and IL-4) was performed by flow cytometry after 18 h and after restimulation of expanded gamma delta T cells. The early activation of resting gamma delta T cells was characterized by the induction of IFN-gamma. Priming under Th1 conditions induced a Th1 profile characterized by increased secretion of IFN-gamma and TNF-alpha, while Th2 conditions caused increased production of IL-4 (Th2 profile) by the gamma delta T cells. These results indicate that the major subset of human gamma delta T cells can be polarized into either Th1 or Th2 cytokine pattern depending on the cytokine milieu in which contact with antigen occurs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11748927     DOI: 10.1006/cimm.2001.1850

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  62 in total

1.  Integrated immune responses to infection - cross-talk between human gammadelta T cells and dendritic cells.

Authors:  Matthias Eberl; Hassan Jomaa; Adrian C Hayday
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

Review 2.  Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity.

Authors:  Marc Bonneville; Rebecca L O'Brien; Willi K Born
Journal:  Nat Rev Immunol       Date:  2010-06-11       Impact factor: 53.106

3.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 4.  Mechanisms underlying lineage commitment and plasticity of human γδ T cells.

Authors:  Nadia Caccamo; Matilde Todaro; Guido Sireci; Serena Meraviglia; Giorgio Stassi; Francesco Dieli
Journal:  Cell Mol Immunol       Date:  2012-10-22       Impact factor: 11.530

Review 5.  Understanding the complexity of γδ T-cell subsets in mouse and human.

Authors:  Dick J Pang; Joana F Neves; Nital Sumaria; Daniel J Pennington
Journal:  Immunology       Date:  2012-07       Impact factor: 7.397

Review 6.  γδ T-APCs: a novel tool for immunotherapy?

Authors:  Bernhard Moser; Matthias Eberl
Journal:  Cell Mol Life Sci       Date:  2011-05-15       Impact factor: 9.261

7.  Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy.

Authors:  David Vermijlen; Peter Ellis; Cordelia Langford; Anne Klein; Rosel Engel; Katharina Willimann; Hassan Jomaa; Adrian C Hayday; Matthias Eberl
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

Review 8.  Regulatory functions of γδ T cells.

Authors:  Christian Peters; Dieter Kabelitz; Daniela Wesch
Journal:  Cell Mol Life Sci       Date:  2018-03-08       Impact factor: 9.261

9.  Identification of a new tuberculosis antigen recognized by γδ T cell receptor.

Authors:  Xueyan Xi; Xiqin Han; Liang Li; Zhendong Zhao
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

Review 10.  Complex role of γδ T-cell-derived cytokines and growth factors in cancer.

Authors:  Andrew G Ramstead; Mark A Jutila
Journal:  J Interferon Cytokine Res       Date:  2012-10-18       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.